Roche RIA and Abbott EIA carcinoembryonic antigen assays compared.

Area of Science:

• Clinical Chemistry
• Oncology Diagnostics
• Biomarker Analysis

Background:

• Carcinoembryonic antigen (CEA) is a tumor marker used in cancer monitoring.
• Different diagnostic kits for CEA may yield varying results.
• Standardization of CEA assays is crucial for accurate patient management.

Purpose of the Study:

• To evaluate and compare the performance of Roche Diagnostics' RIA-CEA and Abbott Diagnostics' EIA-CEA methods.
• To assess precision, reference intervals, concordance, and correlation of CEA levels in patients with malignant diseases.
• To determine if these two CEA assays can be used interchangeably in clinical practice.

Main Methods:

• Comparative analysis of Roche RIA-CEA and Abbott EIA-CEA assays.
• Evaluation of precision, normal reference intervals, and correlation using patient plasma samples.
• Analysis of concordance in 138 patients with primary breast, colon, lung, or pancreas carcinomas, stratified by disease extent.
• Statistical analysis including regression and paired data analysis to identify discordances.

Main Results:

• Both Roche and Abbott CEA assays demonstrated comparable precision.
• Upper limits of normal were 5.0 µg/L for Roche and 4.6 µg/L for Abbott.
• A high correlation (r=0.948) was observed, but concordance was only 78.7%.
• Significant discordances were noted in advanced cancers, particularly colon and pancreatic cancers, with method-specific differences in CEA levels.

Conclusions:

• The Roche RIA-CEA and Abbott EIA-CEA methods are not interchangeable due to observed discordances, especially in disseminated cancers.
• CEA heterogeneity and hepatic metabolism may contribute to assay variability.
• Establishing method-specific baseline CEA values is essential for accurate monitoring of cancer patients.